Literature DB >> 34516507

Postoperative complications observed with robotic versus laparoscopic surgery for the treatment of rectal cancer: An updated meta-analysis of recently published studies.

Chengkui Liu1, Xiaoqing Li2, Qingfeng Wang1.   

Abstract

BACKGROUND: This is an updated meta-analysis comparing the postoperative complications observed with robotic versus laparoscopic surgery (LS) for the treatment of rectal cancer.
METHODS: Cochrane central, MEDLNE (Medical Literature Analysis and Retrieval System Online), EMBASE (Excerpta Medica dataBASE), Google Scholar, Web of Science and http://www.ClinicalTrials.gov were searched for studies (published after the year 2015), comparing robotic versus LS for the treatment of rectal cancer. The postoperative outcomes were considered as the endpoints in this analysis. RevMan 5.4 was used to carry out the statistical analysis. Risk ratio (RR) with 95% confidence intervals (CI) were used to represent the results following data analysis.
RESULTS: A total number of 22,744 participants were included in this study whereby 9178 participants were assigned to the robotic surgery and 13,566 participants were assigned to the LS group. The time period of patients' enrollment varied from years 2007 to 2017. Our results showed that overall complications (RR: 0.91, 95% CI: 0.71-1.17; P = .45), wound complications (RR: 0.81, 95% CI: 0.64-1.04; P = .09), anastomotic leak (RR: 1.12, 95% CI: 0.88-1.42; P = .37), anastomotic bleeding (RR: 0.88, 95% CI: 0.29-2.64; P = .82), stoma-related complications (RR: 0.88, 95% CI: 0.24-3.21; P = .85), intra-abdominal abscess (RR: 0.53. 95% CI: 0.22-1.31; P = .17), urinary tract infection (RR: 0.94, 95% CI: 0.53-1.66; P = .83), enterocolitis (RR: 1.35, 95% CI: 0.38-4.71; P = .64), reoperation (RR: 0.85, 95% CI: 0.46-1.54; P = .58), and mortality (RR: 0.75, 95% CI: 0.34-1.62; P = .46) were not significantly different between robotic-assisted versus LS for rectal cancer. Postoperative ileus (RR: 1.21, 95% CI: 0.81-1.81; P = .34), readmission (RR: 1.17, 95% CI: 0.75-1.83; P = .48), and urinary retention (RR: 0.51, 95% CI: 0.21-1.23; P = .14) were also similarly manifested.
CONCLUSIONS: In this updated meta-analysis, both robotic and laparoscopic surgeries were equally effective for the treatment of rectal cancer. Similar postoperative complications were observed. However, our analysis was restricted only to postoperative outcomes, parameters such as duration of surgery were not taken into consideration.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Year:  2021        PMID: 34516507      PMCID: PMC8428752          DOI: 10.1097/MD.0000000000027158

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


Introduction

Today, colorectal cancer, including approximately 30% of cases of rectal cancer, is rapidly increasing.[ A family history of colorectal cancer, an advanced age, consumption of high amount of red meat, food products high in fats, low calcium and low fiber, pre-existing irritable bowel diseases, obesity, rectal polyps are all risk factors for the development of colorectal cancer.[ This disease is life-threatening, and if regular health check-ups are not done, colorectal carcinoma might have reached an advanced stage when discovered. If detected earlier, surgery could prevent the spread of colorectal cancer.[ With progress in technology as well as in operative techniques, laparoscopic surgery (LS)[ and most recently robotic assisted[ surgery have now become the possible treatment strategies for colorectal carcinoma. Several meta-analyses and systematic reviews have been carried out to compare laparoscopic versus robotic assisted surgeries for the treatment of rectal cancers[ However, shortcomings were observed. In one analysis, the authors stated that the quality of the evidence was moderate for most outcomes.[ In an overview of systematic reviews with quality assessment of current evidence, the authors concluded that high-quality systematic reviews in which selection of high quality studies and combined with adequate methodology would be needed to clarify the true efficacy of robotic surgery.[ Nevertheless, with further improvement in more sophisticated equipment and modern tools which are being used today, we aimed to include only recently published studies (after the year 2015), to compare the postoperative complications (POC) observed with robotic versus LS for the treatment of rectal cancer.

Methods

Data sources

Cochrane central, MEDLNE (Medical Literature Analysis and Retrieval System Online), EMBASE (Excerpta Medica dataBASE), Google Scholar, Web of Science and http://www.ClinicalTrials.gov were searched for publications comparing robotic versus LS for the treatment of rectal cancer.

Search terms and searched strategies

English-based publications were considered relevant in this analysis. The following searched terms or phrases were used: Robotic, laparoscopic, rectal cancer; Robotic, laparoscopic, rectal carcinoma; Robotic surgery, LS, rectal cancer; Rectal cancer and surgery; Rectal carcinoma and surgery. Not a single abbreviation was required to be used in the search process.

Inclusion and exclusion criteria

The inclusion criteria were: Studies that compared robotic versus LS for the treatment of rectal cancer; Studies that were published after the year 2015; Studies that reported POC; Studies that consisted of dichotomous data; Studies which were published in English language. The exclusion criteria were: studies that did not compare robotic versus LS for the treatment of rectal cancer; studies that compared robotic versus LS for the treatment of rectal cancer but were published before or during the year 2015; non-English publications; studies that did not report postoperative outcomes; studies that were repeatedly found in different search databases.

Outcomes and follow-UPS

The outcomes which were reported in the original studies have been listed in Table 1.
Table 1

Outcomes reported.

StudiesOutcomesFollow-up time periods
Bo 2019[13]Wound complication, UTI, urinary retention, stress ulcer, pulmonary, liver dysfunction, intraluminal bleeding, intra-abdominal abscess, intestinal fistula, injury of urinary system, infection via catheter, ileus, cerebrovascular, enterocolitis, cardiac, anastomosis bleeding, anastomosis leakage30 days postoperative
Chen 2017[14]Wound complication, acute myocardial infarction, pulmonary collapse, acute respiratory failure, general surgical complications, paralytic ileus, peritonitis and retroperitoneal infections, hemoperitoneum, postoperative infection5 years period
Colombo 2016[15]Anastomotic leakage, ischemic colitis, postoperative ileus, peri-anastomotic abscess, early postoperative surgery, mortality due to cancer15–35 months
Feroci 2016[16]Anastomotic leak, peritoneal hemorrhage, stomal stricture, wound infection, ileus, abdominal pain, reoperation, mortality for rectal cancer37.4 months
Galata 2019[17]Reoperation, anastomotic leak, postoperative ileus, intra-abdominal abscess, readmission, other complications, surgical site infection12 months
Garfinkle 2019[18]Superficial surgical site infection, deep surgical site infection, wound dehiscence, anastomotic leak, postoperative ileus, pneumonia, urinary tract infection, pulmonary embolism, deep vein thrombosis, acute renal failure, stroke, cardiac arrest, sepsis, septic shock, reoperation, mortality, readmission30 days
Hopkins 2019[19]30 days mortality, 90 days mortality, readmission3 months
Lelpo 2017[20]Overall complications, readmission, anastomotic leakage, intra-abdominal abscess5 years
Jayne 2017[21]Overall postoperative complications, mortality within 30 days and above 30 days, gastrointestinal complication, urinary complication, surgical site infection, respiratory complication, cardiac complication, cerebrovascular complication, anastomotic leakage6 months
Kim 2016[22]Anastomotic leakage, reoperation
Kim 2017A[23]Anastomotic leakage, ileus, acute voiding difficulty, stoma-related complication, wound discharge, bleeding
Kim 2017B[24]Anastomotic leakage, wound infection, ileus, bleeding, postoperative mortality5 years
Law 2016[25]Overall complications, 30-day mortality, reoperation, anastomotic leak, ileus, wound complication, urine retention, deep vein thrombosis, cardiac complication30 days
Liu 2019[26]Wound infection, urinary tract infection, urinary retention, anastomotic leak, anastomotic bleeding, small bowel obstruction30 days
Shiomi 2019[27]Anastomotic leakage, anastomotic bleeding, prolonged ileus, urinary retention, urinary tract infection, wound infection, pelvic abscess, enterocolitis, pneumonia-
Outcomes reported. The postoperative outcomes which were assessed included: overall complications; wound complication; anastomotic leak; anastomotic bleeding; stoma-related complication; postoperative ileus; intra-abdominal abscess; urinary retention; enterocolitis; urinary tract infection; readmission; reoperation; mortality.

Data extraction and quality assessment

The authors independently extracted data from the original studies. Data including the surname of the first authors of each paper, the year of publication, the POC which were reported, the total number of participants who were treated with robotic and laparoscopic surgeries respectively, the methodological quality of the studies, the follow-up time period, the baseline features including age, percentage of male participants, and the body mass index of the participants, the types of study, the patients’ enrollment time period, and the number of events were carefully extracted. Any disagreement which followed were carefully discussed and resolved among the authors. The methodological quality of the studies were assessed by the Cochrane tool for the randomized trials[ and by the Newcastle Ottawa Scale (NOS)[ for the observational studies. A grade ranging from A to C was allotted, grade A representing a low risk of bias whereas grade C represented a high risk of bias.

Statistical analysis

This is a meta-analysis including data which were extracted from previously published studies. RevMan 5.4 was used to carry out the statistical analysis. Heterogeneity was assessed by 2 simple statistical test: the Q statistic test and the I2 statistic test. A P value ≤.05 was considered statistically significant. A result with a P value >.05 was considered insignificant statistically. For the I2 test, the lower the I2 value, the lower the heterogeneity. If an I2 value of <50% was obtained, a fixed effect model was used or else, a random statistical model was used during the data analysis. Risk ratio (RR) with 95% confidence intervals (CI) were used to represent the results following data analysis. Sensitivity analysis was also carried out. An exclusion method was used to carry sensitivity analysis. Each study was excluded one by one, and an analysis was carried out each time excluding that particular study. The results which were obtained were compared with the main results of this analysis for any significant change. Publication bias was also assessed by visually observing funnel plots for any asymmetry.

Ethical approval

This study is a meta-analysis of previously published studies and therefore, an ethical approval was not required.

Results

Search outcomes

The preferred reporting items for systematic reviews and meta-analyses (PRISMA) guideline was followed.[ A total number of 1276 publications were obtained. Following an initial assessment after carefully studying the abstracts and titles, 895 publications were excluded. Two hundred and fifty five (255) repeated studies were further eliminated among the remaining publications. One hundred and twenty six (126) full text articles were assessed for eligibility. Based on the inclusion and exclusion criteria, further eliminations were carried due to the following reasons: relevant studies which were published on or before the year 2015 (n = 34), non-English publications (n = 7); systematic reviews and meta-analyses or literature reviews (42); case studies (n = 28). Finally, only 15 studies[ were included in this analysis as shown in Fig. 1.
Figure 1

Flow diagram showing the study selection.

Flow diagram showing the study selection.

General and baseline features

The main features of the studies have been listed in Table 2. Two studies were randomized trials whereas the remaining 13 studies were observational studies. A total number of 22,744 participants were included in this study whereby 9178 participants were assigned to the robotic surgery and 13,566 participants were assigned to the LS groups as shown in Table 2. The time period of patients’ enrollment varied from years 2007 to 2017.
Table 2

Main features of the studies.

StudiesType of studyYear of patients enrollmentNo. of participants assigned to robotic assisted surgery (n)No. of participants assigned to laparoscopic assisted surgery (n)Bias risk grade
Bo 2019Retrospective2010–20165561139B
Chen 2017Retrospective2008–201247445578B
Colombo 2016OS2009–20136060B
Feroci 2016Retrospective2008–20145358B
Galata 2019Prospective2016–20171833B
Garfinkle 2019Prospective2016154213B
Hopkins 2019Prospective2010–201424725144B
Lelpo 2017OS2010–201786112B
Jayne 2017Randomized trial2011–2014237234B
Kim 2016Prospective2010–20123366B
Kim 2017ARandomized trial2012–20156673B
Kim 2017BRetrospective2007–2014272460B
Law 2016Prospective2008–2015220171B
Liu 2019Retrospective2015–201780116B
Shiomi 2019Retrospective2010–2015127109B
Total no of patients (n)917813,566
Main features of the studies. Following a methodological assessment, a grade B was allotted to the studies representing a moderate risk of bias. The baseline features of the participants have been listed in Table 3. According to Table 3, the mean age of the participants from the robotic surgery group varied from 57.0 to 66.0 years and the mean age of those participants who were assigned to the laparoscopic group varied from 58.0 to 68.0 years. The percentage of male participants from the robotic group varied from 50.9% to 77.3%, whereas the percentage of male participants who were assigned to the laparoscopic group varied from 56.7% to 72.4% as shown in Table 3. The value for body mass index was also given in the table.
Table 3

Baseline features of the participants.

StudiesAge, yrMales (%)BMI, kg/m2
RS/LSRS/LSRS/LS
Bo 201957.0/58.062.4/62.223.3/23.0
Chen 2017
Colombo 201662.0/60.066.7/70.025.8/23.8
Feroci 201666.0/66.050.9/72.424.6/24.6
Galata 201960.0/62.326.0/27.4
Garfinkle 201961.9/63.868.8/59.628.0/27.3
Hopkins 201959.0/59.066.0/62.0
Lelpo 201763.9/61.655.8/59.826.1/25.7
Jayne 201764.4/65.567.9/67.9
Kim 201657.0/58.269.7/69.723.2/23.3
Kim 2017A60.4/59.777.3/71.224.1/23.6
Kim 2017B59.2/63.968.0/64.323.5/23.3
Law 201665.0/67.067.3/56.724.9/24.6
Liu 201962.0/59.766.3/62.123.1/23.3
Shiomi 201965.0/68.073.2/59.623.7/22.8
Baseline features of the participants.

Main results of this analysis

Our results showed that overall complications (RR: 0.91, 95% CI: 0.71–1.17; P = .45), wound complications (RR: 0.81, 95% CI: 0.64–1.04; P = .09), anastomotic leak (RR: 1.12, 95% CI: 0.88–1.42; P = .37), anastomotic bleeding (RR: 0.88, 95% CI: 0.29–2.64; P = .82), stoma-related complications (RR: 0.88, 95% CI: 0.24–3.21; P = .85), intra-abdominal abscess (RR: 0.53, 95% CI: 0.22–1.31; P = .17), urinary tract infection (RR: 0.94, 95% CI: 0.53–1.66; P = .83), enterocolitis (RR: 1.35, 95% CI: 0.38–4.71; P = .64), reoperation (RR: 0.85, 95% CI: 0.46–1.54; P = .58), mortality (RR: 0.75, 95% CI: 0.34–1.62; P = .46) were not significantly different between robotic-assisted versus LS for rectal cancer as shown in Fig. 2. Postoperative ileus (RR: 1.21, 95% CI: 0.81–1.81; P = .34) and urinary retention (RR: 0.51, 95% CI: 0.21–1.23; P = .14) were also similarly manifested as shown in Fig. 3. In addition, there was also no significant difference in readmission (RR: 1.17, 95% CI: 0.75–1.83; P = .48) among patients who were treated with robotic versus LS as shown in Fig. 4.
Figure 2

Postoperative outcomes observed with robotic versus laparoscopic surgery for the treatment of rectal cancer (Part A).

Figure 3

Postoperative outcomes observed with robotic versus laparoscopic surgery for the treatment of rectal cancer (Part B).

Figure 4

Readmission observed with robotic versus laparoscopic surgery for the treatment of rectal cancer.

Postoperative outcomes observed with robotic versus laparoscopic surgery for the treatment of rectal cancer (Part A). Postoperative outcomes observed with robotic versus laparoscopic surgery for the treatment of rectal cancer (Part B). Readmission observed with robotic versus laparoscopic surgery for the treatment of rectal cancer. The results were summarized in Table 4.
Table 4

Results of this analysis.

Outcomes which were assessedRR with 95% CIP valueI2 value (%)
Overall complications0.91 [0.71–1.17].450
Wound complication0.81 [0.64–1.04].0922
Anastomotic leak1.12 [0.88–1.42].370
Anastomotic bleeding0.88 [0.29–2.64].820
Stoma-related complication0.88 [0.24–3.21].859
Post-operative ileus1.21 [0.81–1.81].3471
Intra-abdominal abscess0.53 [0.22–1.31].170
Urinary retention0.51 [0.21–1.23].1459
Urinary tract infection0.94 [0.53–1.66].830
Enterocolitis1.35 [0.38–4.71].6437
Re-admission1.17 [0.75–1.83].4857
Re-operation0.85 [0.46–1.54].580
Mortality0.75 [0.34–1.62].460
Results of this analysis. Consistent results were obtained throughout. There was no evidence of publication bias when visually assessing the funnel plot which was represented by Fig. 5.
Figure 5

Funnel plot showing the assessment of publication bias.

Funnel plot showing the assessment of publication bias.

Discussion

Using the most recent data (studies published after the year 2015), we aimed to compare the POC observed with robotic versus LS for the treatment of rectal cancer. Our results did not show any significant difference in POC between robotic and LS for the treatment of rectal carcinoma. A similar risk of overall complications, including anastomotic leak and bleeding, intra-abdominal abscess, stoma-related complications, urinary tract infections, urinary retention, enterocolitis, readmission, reoperation, and mortality was observed between these two categories of treatment. Another meta-analysis focusing on rectal cancer showed POC to be similar with both robotic and LS.[ It should be noted that the analysis consisted of 16 studies which were published before July 2011 whereas our current analysis included 15 studies which were published after the year 2015. A meta-analysis which was published in the year 2015, and including 17 studies with 2224 participants showed robotic assisted surgery to be a good alternative to LS and the authors also showed that robotic surgery could enhance postoperative recovery in patients with rectal cancer, and had better recovery in voiding and sexual function.[ Nevertheless, another meta-analysis published in the year 2017, comparing robotic-assisted versus conventional laparoscopic operation in anus-preserving rectal cancer showed the Da Vinci robot to be better compared with LS in terms of POC, blood loss, hospital stay, conversion to open surgery when compared with the LS.[ However, LS had an advantage in terms of operative time, but since our analysis was only specifically based on postoperative outcomes, we did not compare the duration of surgery, conversion to open surgery and hospital stay. In an observational study of patients outcomes from a district general hospital with over a decade of experience with robotic rectal cancer surgery, where 337 patients were included, the authors demonstrated how the selective use of robotic surgery by a group of rectal cancer team could help to decrease the rate of rectal cancer recurrence as well as decrease permanent stoma rates.[ Our current analysis only focused on the postoperative outcomes observed with robotic versus LS for rectal cancer. We did not assess the duration of surgery or the conversion of invasive to open surgery.[ Nevertheless, based on previously published studies, it was found that robotic assisted surgery was better in terms of less blood loss, less conversion to open surgery, but it was associated with a longer duration of surgery compared with the conventional LS.[ Micro Hand S, a Chinese surgical robot, was recently introduced clinically, to be used as a novel robotic platform. When this robotic approach surgical procedure was compared with other conventional approaches, the total rate of surgical success was similar.[ The authors concluded that this robotic surgical approach was feasible and safe to be used showing comparable postoperative outcomes, but with superiority in blood loss, bowel function recovery, and length of hospital stay. However, the operative time was longer with the robotic approach when compared with the other conventional approaches. It is also believed that as costs and operating time decline with robotic surgery in the future as technology progresses, robotic surgery might even replace the traditional laparoscopic techniques one day.[ However, even though many published studies have shown the clinical benefits of robotic surgery for patients with rectal carcinoma, critically low quality evidence suggests that robotic-assisted surgery for rectal cancers decreased the likelihood of conversion to open surgery, but other clinical benefits remain unclear.[ The authors finally requested high qualities systematic reviews to clarify this issue.

Limitations

This study also has limitations. First of all, only a few outcomes were common in almost all the studies. Therefore, we could not include all the studies when assessing each of the outcomes. Secondly, the follow up time period was not same in all the studies. This could have affected the results of this analysis. Another limitation was the fact that data which were extracted from randomized trials and observational studies combined and analyzed. This might have had an impact on the final results. Also, our analysis is an updated version including only studies which were published after the year 2015. This could also have an impact on the final outcome of this analysis and this study might only be a subtype of previously published meta-analyses. Moreover, the length period of disease was ignored in this analysis. It might be possible that the cause of mortality was related to the cancer itself instead to the surgery. Therefore, this could be also another limitation when assessing for mortality.

Conclusions

In this updated meta-analysis, both robotic and LS were equally effective for the treatment of rectal cancer. Similar POC were observed. However, our analysis was restricted only to postoperative outcomes, parameters such as duration of surgery were not taken into consideration.

Author contributions

The authors Chengkui Liu, Xiaoqing Li, and Qingfeng Wang were responsible for the conception and design, acquisition of data, analysis and interpretation of data, drafting the initial manuscript and revising it critically for important intellectual content. All the authors agreed and approved the manuscript as it is. Conceptualization: Chengkui Liu, Xiaoqing Li, Qingfeng Wang. Data curation: Chengkui Liu, Xiaoqing Li, Qingfeng Wang. Formal analysis: Chengkui Liu, Xiaoqing Li, Qingfeng Wang. Funding acquisition: Chengkui Liu, Xiaoqing Li, Qingfeng Wang. Investigation: Chengkui Liu, Xiaoqing Li, Qingfeng Wang. Methodology: Chengkui Liu, Xiaoqing Li, Qingfeng Wang. Project administration: Chengkui Liu, Xiaoqing Li, Qingfeng Wang. Resources: Chengkui Liu, Xiaoqing Li, Qingfeng Wang. Software: Chengkui Liu, Xiaoqing Li, Qingfeng Wang. Supervision: Chengkui Liu, Xiaoqing Li, Qingfeng Wang. Validation: Chengkui Liu, Xiaoqing Li, Qingfeng Wang. Visualization: Chengkui Liu, Xiaoqing Li, Qingfeng Wang. Writing – original draft: Chengkui Liu, Xiaoqing Li, Qingfeng Wang. Writing – review & editing: Chengkui Liu, Xiaoqing Li, Qingfeng Wang.
  33 in total

1.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.

Authors:  Andreas Stang
Journal:  Eur J Epidemiol       Date:  2010-07-22       Impact factor: 8.082

Review 2.  Towards risk-stratified colorectal cancer screening. Adding risk factors to the fecal immunochemical test: Evidence, evolution and expectations.

Authors:  Wessel van de Veerdonk; Sarah Hoeck; Marc Peeters; Guido Van Hal
Journal:  Prev Med       Date:  2019-06-04       Impact factor: 4.018

Review 3.  Robot-assisted versus laparoscopic-assisted surgery for colorectal cancer: a meta-analysis.

Authors:  Xuan Zhang; ZhengQiang Wei; MengJun Bie; XuDong Peng; Cheng Chen
Journal:  Surg Endosc       Date:  2016-07-11       Impact factor: 4.584

4.  Comparison of outcome and cost among open, laparoscopic, and robotic surgical treatments for rectal cancer: A propensity score matched analysis of nationwide inpatient sample data.

Authors:  Szu-Ta Chen; Meng-Che Wu; Tzu-Chun Hsu; Debra W Yen; Chia-Na Chang; Wan-Ting Hsu; Chia-Chun Wang; Matthew Lee; Shing-Hwa Liu; Chien-Chang Lee
Journal:  J Surg Oncol       Date:  2017-12-28       Impact factor: 3.454

5.  Robotic versus laparoscopic rectal resection surgery: Short-term outcomes and complications: A retrospective comparative study.

Authors:  Tang Bo; Li Chuan; Liu Hongchang; Zhang Chao; Luo Huaxing; Yu Peiwu
Journal:  Surg Oncol       Date:  2019-02-04       Impact factor: 3.279

6.  Robotic Versus Conventional Laparoscopic Surgery for Colorectal Cancer: A Systematic Review and Meta-Analysis with Trial Sequential Analysis.

Authors:  Ka Ting Ng; Azlan Kok Vui Tsia; Vanessa Yu Ling Chong
Journal:  World J Surg       Date:  2019-04       Impact factor: 3.352

7.  Comparison of short-term and oncologic outcomes of robotic and laparoscopic resection for mid- and distal rectal cancer.

Authors:  Wai Lun Law; Dominic C C Foo
Journal:  Surg Endosc       Date:  2016-10-26       Impact factor: 4.584

8.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  BMJ       Date:  2009-07-21

9.  Minimal access rectal cancer surgery: an observational study of patient outcomes from a district general hospital with over a decade of experience with robotic rectal cancer surgery.

Authors:  Henry S Tilney; Jeremy R Huddy; A Shiyam Nizar; Ralph Smith; A Mark Gudgeon
Journal:  Colorectal Dis       Date:  2021-06-22       Impact factor: 3.788

10.  Laparoscopic Surgery for Colorectal Cancer in Korea: Nationwide Data from 2013 to 2018.

Authors:  Sun Jin Park; Kil Yeon Lee; Suk-Hwan Lee
Journal:  Cancer Res Treat       Date:  2020-04-06       Impact factor: 4.679

View more
  1 in total

1.  A retrospective study of post-operative complications and cost analysis in robotic rectal resection versus laparoscopic rectal resection.

Authors:  Muhammad Ali; Xiaodong Zhu; Yang Wang; Jianyue Ding; Qi Zhang; Qiannan Sun; Shantanu Baral; Daorong Wang
Journal:  Front Surg       Date:  2022-08-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.